| | ID | Diagnostic criteria | Type of AMI | Sample size (I/C) | Baseline | Duration of treatment | Follow-up | Experiment group | Control group | Outcomes |
| | Gao et al. 2008 [24] | 2004 ACC/AHA | STEMI | 61 (31/30) | Yes | 2 weeks | 2 weeks | CT + DHI
40 mL.qd.ivd.gtt | CT (+PCI) | Recurrent angina, ECG, and aPTT |
| |
Gui 2009 [25] | Not specific | Unclear | 48 (26/22) | Yes | 2 weeks | 2 weeks | CT + DHI
20 mL.qd.ivd.gtt | CT (+thrombolysis) | Mortality, recurrent AMI, shock, HF, arrhythmia, rehospitalization, recurrent angina, and adverse events |
| | Qiao et al. 2010 [26] | Not specific | Unclear | 80 (40/40) | Yes (narrative only) | 2–4 weeks | 2–4 weeks | CT + DHI
40 mL.qd.ivd.gtt | CT | Arrhythmia, HF, shock, reperfusion, and LEVF |
| | Han 2010 [27] | Not specific | Unclear | 100 (50/50) | Yes (narrative only) | 4 weeks | 4 weeks | CT + DHI
20 mL.qd.ivd.gtt | CT (+thrombolysis) | Mortality, adverse events, and reperfusion rate |
| | Jin et al. 2011 [28] | Not specific | Unclear | 60 (30/30) | Yes | 2 weeks | 2 weeks | CT + DHI
30 mL.qd.ivd.gtt | CT (+thrombolysis) | Myocardial enzyme, arrhythmia, LEVF, WMSI, ECG, t-PA, PAI-1, CRP, and Fib |
| | Tian 2011 [29] | WHO | STEMI | 72 (36/36) | Yes (narrative only) | 2 weeks | 2 weeks | CT + DHI
30 mL.qd.ivd.gtt | CT | Recurrent angina, HF, arrhythmia, ECG, and BP |
| | Hao and Ren 2011 [30] | 2001 CSCCMA | Unclear | 120 (60/60) | Yes (narrative only) | Not specific | Not specific | CT + DHI
30 mL.qd.ivd.gtt | CT (+thrombolysis) | Mortality, shock, HF, reperfusion, arrhythmia, and adverse events |
| | Zhao 2012 [31] | Not specific | Unclear | 56 (30/26) | Yes | 2 weeks | 2 weeks/3 months | CT + DHI
30 mL.qd.ivd.gtt | CT (+thrombolysis) | Mortality, myocardial enzyme, HF, arrhythmia, recurrent AMI, LEVF, rehospitalization, and reperfusion |
| | Han et al. 2012 [32] | 2001 CSCCMA | Unclear | 134 (76/58) | Yes (narrative only) | 2 weeks | 4 weeks | CT + DH
30 mL.qd.ivd.gtt | CT (+thrombolysis) | ECG, arrhythmia, myocardial enzyme, reperfusion, HF, shock, recurrent angina, mortality, and adverse events |
| | Zhang 2012 [33] | 2001 CSCCMA | Unclear | 60 (30/30) | Yes | 1 week | 1 week | CT + DHI
30 mL.qd.ivd.gtt | CT (+thrombolysis) | Arrhythmia, recurrent angina, HF, myocardial enzyme, hs-CRP, NT-pro-BNP, and adverse events |
| | Lu 2012 [34] | 2009 CSCCMA | NSTEMI | 40 (20/20) | Yes | 7–10 days | 7–10 days | CT + DHI
20 mL.qd.ivd.gtt | CT (+PCI) | IL-6, NO, ET, arrhythmia, LEVF, myocardial enzyme, and adverse events |
| | Fan and Zheng 2013 [35] | Not specific | Unclear | 90 (47/43) | Yes (narrative only) | Not specific | Not specific | CT + DHI
(without specific usage) | CT (+thrombolysis) | Mortality, HF, shock, reperfusion, and arrhythmia |
| | Qu et al. 2013 [36] | 2010 CSCCMA | Unclear | 58 (29/29) | Yes | 2 weeks | 2 weeks | CT + DHI
40 mL.qd.ivd.gtt | CT (+thrombolysis) | Arrhythmia, recurrent angina, myocardial enzyme, reperfusion, WMSI, and LEVF |
|
|
